Safe Harbor Statement Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) the belief that Anadys is well-positioned to create value in the evolving HCV landscape; (ii) Anadys' objective to extend the favorable results seen last year when ANA598 was dosed over 12 weeks with the recently initiated Phase IIb study; (iii) the belief that the ANA598 Phase IIb study should set the stage for Phase III development; (iv) the ability for patients to achieve SVR24 in the ANA598 Phase IIb study; (v) the timing, occurrence and outcome of expected milestone events; and (vi) the plans and expected trial design for advancing ANA773 in development for HCV. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into transactions around its product candidates, its abil
|SOURCE Anadys Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved